Cargando…
Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
INTRODUCTION: The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC). METHODS: Forty-one Chinese NPC patients with pul...
Autores principales: | Zhou, Liya, Lin, Jie, Wu, Gang, Chen, Jiawei, Huang, Xiaopeng, Zhang, Shuai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125328/ https://www.ncbi.nlm.nih.gov/pubmed/32280197 http://dx.doi.org/10.2147/DDDT.S244102 |
Ejemplares similares
-
Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021) -
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019) -
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
por: Fang, Shen-Cun, et al.
Publicado: (2017) -
Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis
por: Zhou, Chen, et al.
Publicado: (2020) -
Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study
por: Zhang, Shuai, et al.
Publicado: (2018)